Article
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Cancer research and treatment - 1 Jul 2020
Guo Sanxing, Loibl Sibylle, von Minckwitz Gunter, Darb-Esfahani Silvia, Lederer Bianca, Denkert Carsten
Abstract excerpt
PURPOSE: PIK3CA, encoding for subunit p110a of phosphatidylinositol 3 kinase, is frequently mutated in breast cancer. PIK3CA mutation was predictive for pathological complete response (pCR) in human epidermal growth factor 2 positive breast cancer. This study explores the association of PIK3CA mutation and pCR in triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy. MATERIALS AND METHODS: A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.